DAHUA-TECHNOLOGY
Dahua Technology, a world-leading video-centric smart IoT solution and service provider, officially released the Dahua DeepHub Pro Series at its online global launch. Equipped with ultra-low-latency writing, one-tap wireless screen sharing, built-in camera & microphone and other advanced AI functions, Dahua DeepHub delivers a flexible, multimedia approach to teaching and conferencing, providing participants with an immersive, interactive and content-rich experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005338/en/
Traditional methods of learning in classroom settings have several challenges, including poor interaction between students and teachers, and potentially poor visual clarity from some positions in the room. Dahua’s DeepHub interactive whiteboard is designed to provide a content-rich, interactive and stimulating learning experience in schools and colleges, consigning to history conventional whiteboards and other presenting platforms. (Photo: Business Wire)
“Dahua DeepHub combines Dahua's advantages in core technologies such as video, audio and high-definition video transmission to offer a complete range of smart interactive whiteboards. From entry-level Lite Series to high-end Pro Series, this product meets the growing digitalization and collaboration demands of both business and education customer groups in the modern-day IoT world,” said Josh Wang, Product Manager of Dahua DeepHub.
The online launch highlighted several features of Dahua DeepHub. For instance, it utilizes Zero Air Gap Technology on the screen to reduce parallax for clearer image display. Ink signal latency is also optimized, providing approximately 50 pages or 1,500 strokes of continuous writing.
To enhance visual output and operation, Dahua DeepHub utilizes powerful AI functions including Handwriting Recognition that can recognize intelligible handwritten texts and shapes, and Gesture Control to easily operate the device anywhere in the room. It can even automatically detect and focus on the current speaker for better interaction. Also, on-screen materials can be displayed onto other devices in the room and be edited in real-time through the Two-way Sharing function.
Dahua DeepHub also supports SIMS device management system, allowing IT personnel to fully grasp the operating status of the device. It has flagship smartphone-level chip equipped with 8 execution engine GPU to ensure image rendering capability, and an NPU that offers five tops computing power – another unprecedented feature in the industry.
Furthermore, it operates using a single Type C cable that can replace HDMI, audio and touchscreen cables, and can supply power to external devices. It supports fingerprint access control, AirPlay, Chromecast, Miracast, and Eshare wireless connections, as well as Android 11 and Windows 10 operating systems that can be flexibly switched.
The complete range of Dahua DeepHub Series marks a step forward towards Dahua's goal of empowering cities and enterprises with digital transformation through smart IoT technologies. With more models in the upcoming months, Dahua will continue to deliver better digital experience to global customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005338/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom